Deficient glutamate transport is associated with neurodegeneration in Alzheimer's disease

Annals of Neurology

Volumn 40, Issue 5, 1996, Pages 759-766

  Masliah, E ^a,b   Alford, M ^a   DeTeresa, R ^a   Mallory, M ^a   Hansen, L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; SYNAPTOPHYSIN;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BINDING AFFINITY; COGNITION; CYTOTOXICITY; DISEASE ASSOCIATION; GENE EXPRESSION; GLIOSIS; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; TRANSGENIC ANIMAL;

EID: 0029811226     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400512     Document Type: Article

References (76)

1. Masliah F., Terry R. The role of synaptic pathology in the mechanisms of dementia in Alzheimer's disease. Clin Neurosci 1994;1:192-198
2. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 1995;10:509-519
3. Heinonen O, Soininen H, Sorvari H, et al. Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease. Neuroscience 1995;64:375-384
4. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259
5. Hyman BT, Van Hoesen GW, Kromer LJ, Damasio AR. Perforant pathway changes in the memory impairment of Alzheimer's disease. Ann Neurol 1986;20:472-481
6. Hof PR, Morrison JH. The cellular basis of cortical disconnection in Alzheimer disease and related dementing conditions. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer disease. New York: Raven, 1994:197-230
7. Masliah E, Mallory M, Hansen L, et al. An antibody against phosphorylated neurofilaments identifies a subset of damaged association axons in Alzheimer's disease. Am J Pathol 1993; 142:871-882
8. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580
9. Davies CA, Mann DMA, Sumpter PQ, Yates PO. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987;78:151-164
10. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990;27:457-464
11. Masliah E, Mallory M, Hansen L, et al. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 1994;174:67-72
12. Terry RD, Peck A, DeTeresa R, et al. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981;10:184-192
13. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639
14. Terry RD, Gonatas NK, Weiss M. Ultrastructural studies in Alzheimer's presenile dementia. Am J Pathol 1964;44:269-297
15. Cowburn RF, Hardy JA, Roberts PJ. Glutamatergic neurotransmission in Alzheimer's disease. Biochem Soc Trans 1990; 18:390-392
16. Perry EK, Perry RH, Blessed G, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia: CAT and GAD activities in necropsy tissue. J Neurol Sci 1977;34:247-265
17. Palmer AM, Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J 1990;2745:2752
18. Lassmann H, Weiler R, Fischer P, et al. Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles. Neuroscience 1992;46:1-8
19. Masliah E, Mallory M, Hansen L, et al. Patterns of aberrant sprouting in Alzheimer disease. Neuron 1991;6:729-739
20. Masliah E, Terry R. The role of synaptic proteins in the pathogenesis of disorders of the central nervous system. Brain Pathol 1993;3:77-85
21. Masters CL, Multhaup G, Simms G, et al. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J 1985;4:2757-2763
22. Selkoe DJ. Amyloid β protein precursor and the pathogenesis of Alzheimer's disease. Cell 1989;58:611-612
23. Goate A, Chartier-Harlin M-C, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704
24. Clark RF, Goate AM. Molecular genetics of Alzheimer's disease. Arch Neurol 1993;50:1164-1172
25. Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991;254:97-99
26. Chartier-Harlin M-C, Crawford F, Houlden H, et al. Earlyonset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 1991;353: 844-846
27. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995;373:523-527
28. Shimokawa M, Yanagisawa K, Nishiye H, Miyatake T. Identification of amyloid precursor protein in synaptic plasma membrane. Biochem Biophys Res Commun 1993;196:240-244
29. Card JP, Meade RP, Davis LG. Immunocytochemical localization of the precursor of the precursor protein for β-amyloid in the rat central nervous system. Neuron 1988;1:835-846
30. Arai H, Lee VM-Y, Messinger ML, et al. Expression patterns of β-amyloid precursor protein (β-APP) in neural and nonneural tissues from Alzheimer's disease and control subjects. Ann Neurol 1991;30:686-693
31. Schubert W, Prior R, Weidemann A, et al. Localization of Alzheimer beta A4 amyloid precursor protein at central and peripheral synaptic sites. Brain Res 1991;563:184-194
32. Masliah E, Mallory M, Hansen L, et al. Localization of amyloid precursor protein in GAP43-immunoreactive aberrant sprouting neuntes in Alzheimer's disease. Brain Res 1992;574: 312-316
33. Askanas V, Engel WK, Alvarez RB. Strong immunoreactivity of β-amyloid precursor protein, including the β-amyloid protein sequence, at human neuromuscular junctions. Neurosci Lett 1992;143:96-100
34. Saitoh T, Roch J-M, Lin LW, et al. The biological function of amyloid β/A4 protein precursor. In: Masters CL, Beyreuther K, Trillet M, Christen I, eds. Amyloid protein precursor in development, aging and Alzheimer's disease. Fondation IP-SEN. New York: Springer, 1994:90-99
35. Mucke L, Masliah E, Johnson WB, et al. Synaptotrophic effects of human amyloid β protein precursors in the cortex of transgenic mice. Brain Res 1994;666:151-167
36. Masliah E, Mallory M, Alford M, et al. Abnormal synaptic regeneration in hAPP695 transgenic and APOE knockout mice. In: Iqbal K, Mortimer JA, Winblad B, Wisniewski HM, eds. Research advances in Alzheimer's disease and related disorders. Chichester: John Wiley & Sons, 1995:405-414
37. Roch J-M, Masliah E, Roch-Levecq A-C, et al. Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid β/A4 protein precursor. Proc Natl Acad Sci USA 1994;91:7650-7654
38. Mucke L, Abraham CR, Ruppe MD, et al. Protection against HIV-1 gp120-induced brain damage by neuronal overexpression of human amyloid precursor protein (hAPP). J Exp Med 1995;181:1551-1556
39. Mattson MP, Cheng B, Culwell AR, et al. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein. Neuron 1993; 10:243-254
40. Bowes MP, Masliah E, Chen B-L, et al. Reduction of neurological damage by a trophic peptide segment of the amyloid β/A4 protein (APP). Exp Neurol 1994;129:1-8
41. Smith-Swintosky VL, Pettigrew LC, Craddock SD, et al. Secreted forms of β-amyloid precursor protein protect against ischemic brain injury. J Neurochem 1994;63:781-784
42. Mattson MP, Cheng B, Smith-Swintosky VL. Mechanisms of neurotrophic factor protection against calcium- and free radical-mediated excitotoxic injury: implications for treating neurodegenerative disorders. Exp Neurol 1993;124:89-95
43. Mattson MP, Tomaselli KJ, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res 1993;621:35-49
44. Kanai Y, Stelzner M, Nubberg S, et al. The neuronal and epithelial human high affinity glutamate transporter. J Biol Chem 1994;269:20599-20606
45. Greenamyre JT, Porter RHP. Anatomy and physiology of glutamate in the CNS. Neurology 1994;44(suppl):S7-S13
46. Kanai Y, Smith CP, Hediger MA. The elusive transporters with a high affinity for glutamate. Trends Neurosci 1993;16:359-365
47. Balcar VJ, Li Y. Heterogeneity of high affinity uptake of L-glutamate and L-aspartate in the mammalian central nervous system. Life Sci 1992;51:1467-1478
48. Pines G, Danbolt NC, Bjoras M, et al. Cloning and expression of a rat brain L-glutamate transporter. Nature 1992;360:464-467
49. Kanai Y, Hediger MA. Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 1992;360:467-471
50. +-dependent glutamate/ aspartate transporter from rat brain. Proc Natl Acad Sci USA 1992;89:10955-10959
51. Kanai Y, Nussberger S, Romero MF, et al. Electrogenic properties of the epithelial and neuronal high affinity glutamate transporter. J Biol Chem 1995;270:16561-16568
52. Rothstein JD, Martin L, Levey AI, et al. Localization of neuronal and glial glutamate transporters. Neuron 1994;13:713-725
53. Scott HL, Tannenberg AEG, Dodd PR. Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex. J Neurochem 1995;64:2193-2202
54. Cowburn R, Hardy J, Roberts P, Briggs R. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease. Neurosci Lett 1988;86:109-113
55. Rothstein JD, Van Kammen M, Levey AI, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84
56. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993;90:6591-6595
57. Zagon IS, Higbee BM, Goodman SR. Spectrin subtypes in mammalian brain: an immunoelectron microscopic study. J Neurosci 1986;6:2977-2986
58. Lynch G, Baudry M. Brain spectrin, calpain and long term changes in synaptic efficacy. Brain Res Bull 1987;18:809-815
59. Seubert P, Ivy G, Larson J, et al. Lesions of entorhinal cortex produce a calpain-mediated degradation of brain spectrin in dentate gyrus. I. Biochemical studies. Brain Res 1988;459: 226-232
60. Lowy MT, Wittenberg L, Yamamoto BK. Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem 1995;65:268-274
61. Broroson JR, Marcuccilli CJ, Miller RJ. Delayed antagonism of calpain reduces excitotoxicity in cultured neurons. Stroke 1995;26:1259-1267
62. Masliah E, Iimoto D, Saitoh T, et al. Increased immunoreactivity of brain spectrin in Alzheimer disease: a marker for synapse loss? Brain Res 1990;531:36-44
63. Alford MF, Masliah E, Hansen LA, Terry RD. A simple dot-immunobinding assay for the quantification of synaptophysinlike immunoreactivity in human brain. J Histochem Cytochem 1994;42:283-287
64. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193:265-272
65. Wiedenmann B, Franke WW. Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell 1985;41: 1017-1028
66. Jahn R, Schiebler W, Quiment C, Greengard P. A 38,000-dalton membrane protein (p38) present in synaptic vesicles. Proc Natl Acad Sci USA 1985;82:4137-4141
67. Masliah E, Fagan AM, Terry RD, et al. Reactive synaptogenesis assessed by synaptophysin immunoreactivity is associated with GAP-43 in the dentate gyrus of the adult rat. Exp Neurol 1991;113:131-142
68. Masliah E, Ellisman M, Carragher B, et al. Three-dimensional analysis of the relationship between synaptic pathology and neuropil threads in Alzheimer disease. J Neuropathol Exp Neurol 1992;51:404-414
69. 3H]D-aspartate binding and high-affinity glutamate uptake in the human brain. Neurosci Lett 1986;63:121-124
70. 3H]aspartate binding sites. Life Sci 1993;52:863-868
71. McPherson GA. A practical computer-based approach to the analysis of radioligand binding experiments. Comp Prog Biomed 1983;17:107-113
72. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980;107:220-239
73. Gundersen V, Danbolt NC, Ottersen OP, Storm-Mathisen J. Demonstration of glutamate/aspartate uptake activity in nerve endings by use of antibodies recognizing exogenous D-aspartate. Neuroscience 1993;57:97-111
74. 3H]TCP binding sites in Alzheimer's disease brains. Brain Res 1988;462:76-82
75. Procter AW, Palmer AM, Stratmann GC, Bowen DM. Glutamate/aspartate-releasing neurons in Alzheimer's disease. N Engl J Med 1986;314:1711-1712
76. Choi DW. Ionic dependence of glutamate neurotoxicity. J Neurosci 1987;7:369-379